Table 2 Canonical pathway analysis using ingenuity pathways analysis (IPA; Ingenuity Systems, www.ingenuity.com).
From: Circadian variations in the liver metabolites of medaka (Oryzias latipes)
Ingenuity Canonical Pathways | −log(p-value) | Ratio (ZT16/ZT4) |
|---|---|---|
Lysine Degradation V | 3.8E + 00 | 2.8E − 01 |
Adenine and Adenosine Salvage III | 3.8E + 00 | 4.0E − 01 |
Citrulline-Nitric Oxide Cycle | 3.6E + 00 | 3.6E − 01 |
Guanine and Guanosine Salvage I | 3.0E + 00 | 4.3E − 01 |
Morphine Biosynthesis | 2.9E + 00 | 3.8E − 01 |
Purine Nucleotides Degradation II (Aerobic) | 2.8E + 00 | 2.4E − 01 |
Salvage Pathways of Pyrimidine Ribonucleotides | 2.8E + 00 | 2.4E − 01 |
Arginine Biosynthesis IV | 2.7E + 00 | 2.2E − 01 |
TCA Cycle II (Eukaryotic) | 2.7E + 00 | 2.2E − 01 |
Purine Nucleotides De Novo Biosynthesis II | 2.7E + 00 | 1.7E − 01 |
Nicotine Degradation II | 2.5E + 00 | 3.0E − 01 |
Palmitate Biosynthesis I (Animals) | 2.5E + 00 | 3.0E − 01 |
Glutathione-mediated Detoxification | 2.4E + 00 | 2.7E − 01 |
Lysine Degradation II | 2.3E + 00 | 2.5E − 01 |
Purine Ribonucleosides Degradation to Ribose-1-phosphate | 2.3E + 00 | 2.5E − 01 |
Glutathione Redox Reactions II | 2.3E + 00 | 5.0E − 01 |
Superpathway of Citrulline Metabolism | 2.3E + 00 | 1.7E − 01 |
Glycine Betaine Degradation | 2.2E + 00 | 2.3E − 01 |
Urea Cycle | 2.1E + 00 | 2.1E − 01 |
